Broker recommendations for AbbVie
The AbbVie, Inc. stock is rated at 1.289474 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 17 September, 2020 by a total of 19 brokers. This means that the consensus of the 19 different brokers is leaning toward to buy/moderate buy.
Sell
0 (0%) Underweight
0 (0%) Hold
5 (26.32%) Overweight
1 (5.26%) Buy
13 (68.42%)
Price target by analysts
The 16 latest analyst estimates, per Thursday 10 September, 2020, show the following high, low and average price targets.
Target Average: 110 USD
Target High: 127 USD
Target Low: 96 USD
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020: Comprehensive Listing of 2,300+ Clinical Stage Partnering Deals
Friday, 18 September 2020, 19:30:00
DUBLIN , Sept. 18, 2020 /PRNewswire/ — The “Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020” report has been added to ResearchAndMarkets.com’s offering. The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties.
— Benzinga
AbbVie: High Yield Dividend Anxiety (NYSE:ABBV)
Thursday, 17 September 2020, 22:04:49
Elusive yields during a pandemic force yield-hungry investors to take uncomfortable risks. AbbVie’s Seeking Alpha Quant grade of F for dividend safety is concerning.
— Seeking Alpha
Intrauterine Contraceptive Devices (IUD) Market: COVID-19 Business Continuity Plan | Evolving Opportunities with AbbVie Inc. and Bayer AG | Technavio
Thursday, 17 September 2020, 11:30:00
LONDON–(BUSINESS WIRE)– #GlobalIntrauterineContraceptiveDevicesIUDMarket–The Global Intrauterine Contraceptive Devices (IUD) Market will grow by $ 597.40 mn during 2020-2024
— Business Wire
Global Antibiotics Market- Featuring Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, and Bayer AG, Among Others | Technavio
Thursday, 17 September 2020, 00:30:00
LONDON–(BUSINESS WIRE)– #AntibioticsMarket–The Global Antibiotics Market will grow by USD 4.44 bn during 2020-2024
— Business Wire
AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at Morgan Stanley 18th Annual Global Healthcare Conference (Transcript)
Wednesday, 16 September 2020, 22:37:06
AbbVie Inc. (NYSE:ABBV) Morgan Stanley 18th Annual Global Healthcare Conference September 16, 2020 11:00 AM ET Company Participants Rick Gonzalez – Chairman & Chief Executive Officer Mike Severino – Vice Chairman & President Rob Michael – Executive Vice President & Chief Financial Officer Conference Call Participants Dave Risinger – Morgan Stanley Presentation Dave Risinger Great.
— Seeking Alpha
